Identification of Triple-negative and Basal-like Canine Mammary Carcinomas using Four Basal Markers

Journal of Comparative Pathology

Volumn 148, Issue 4, 2013, Pages 298-306

  Kim, N H ^a   Lim, H Y ^a   Im, K S ^a   Kim, J H ^b,c   Sur, J H ^a  

^a Konkuk University   (South Korea)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Basal like carcinoma; Canine mammary carcinoma; Immunohistochemistry; Triple negative carcinoma

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 14; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P63;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASAL CELL CARCINOMA; BREAST CARCINOMA; CANCER PROGNOSIS; CONTROLLED STUDY; DOG; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MOLECULAR PATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; CARCINOMA; DOG DISEASES; DOGS; ESTROGEN RECEPTOR ALPHA; FEMALE; KERATIN-14; KERATIN-5; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, ANIMAL; PHOSPHOPROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

CANIS FAMILIARIS;

EID: 84876795901     PISSN: 00219975     EISSN: 15323129     Source Type: Journal    
DOI: 10.1016/j.jcpa.2012.08.009     Document Type: Article

References (41)

1. Abd El-Rehim D.M., Pinder S.E., Paish C.E., Bell J., Blamey R.W., et al. Expression of luminal and basal cytokeratins in human breast carcinoma. Journal of Pathology 2004, 203:661-671.
2. Barbareschi M., Pecciarini L., Cangi M.G., Macri E., Rizzo A., et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. American Journal of Surgical Pathology 2001, 25:1054-1060.
3. Bertagnolli A.C., Cassali G.D., Genelhu M.C., Costa F.A., Oliveira J.F., et al. Immunohistochemical expression of p63 and deltaNp63 in mixed tumors of canine mammary glands and its relation with p53 expression. Veterinary Pathology 2009, 46:407-415.
4. Bertucci F., Finetti P., Cervera N., Esterni B., Hermitte F., et al. How basal are triple-negative breast cancers?. International Journal of Cancer 2008, 123:236-240.
5. Camp R.L., Neumeister V., Rimm D.L. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. Journal of Clinical Oncology 2008, 26:5630-5637.
6. Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clinical Cancer Research 2008, 14:1368-1376.
7. Choo J.R., Nielsen T.O. Biomarkers for basal-like breast cancer. Cancers 2010, 2:1040-1065.
8. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research 2007, 13:4429-4434.
9. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.
10. Fadare O., Tavassoli F.A. Clinical and pathologic aspects of basal-like breast cancers. Nature Clinical Practice Oncology 2008, 5:149-159.
11. Fan C., Oh D.S., Wessels L., Weigelt B., Nuyten D.S., et al. Concordance among gene-expression-based predictors for breast cancer. New England Journal of Medicine 2006, 355:560-569.
12. Gama A., Alves A., Gartner F., Schmitt F. p63: a novel myoepithelial cell marker in canine mammary tissues. Veterinary Pathology 2003, 40:412-420.
13. Gama A., Alves A., Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: application of the human classification. Virchow's Archive 2008, 453:123-132.
14. Gama A., Gartner F., Alves A., Schmitt F. Immunohistochemical expression of epidermal growth factor receptor (EGFR) in canine mammary tissues. Research in Veterinary Science 2009, 87:432-437.
15. Goldschmidt M., Pena L., Rasotto R., Zappulli V. Classification and grading of canine mammary tumors. Veterinary Pathology 2011, 48:117-131.
16. Hu Z., Fan C., Oh D.S., Marron J.S., He X., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
17. Kim M.J., Ro J.Y., Ahn S.H., Kim H.H., Kim S.B., et al. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Human Pathology 2006, 37:1217-1226.
18. Klopfleisch R., Gruber A.D. Differential expression of cell cycle regulators p21, p27 and p53 in metastasizing canine mammary adenocarcinomas versus normal mammary glands. Research in Veterinary Science 2009, 87:91-96.
19. Klopfleisch R., von Euler H., Sarli G., Pinho S.S., Gartner F., et al. Molecular carcinogenesis of canine mammary tumors: news from an old disease. Veterinary Pathology 2011, 48:98-116.
20. Madrazo J., Garcia-Fernandez R.A., Garcia-Iglesias M.J., Duran A.J., Espinosa J., et al. The role of CD44 adhesion factor in canine mammary carcinomas. Veterinary Journal 2009, 180:371-376.
21. Matos I., Dufloth R., Alvarenga M., Zeferino L.C., Schmitt F. p63, cytokeratin 5, and P-cadherin: three molecular markers to distinguish basal phenotype in breast carcinomas. Virchow's Archive 2005, 447:688-694.
22. Millanta F., Calandrella M., Bari G., Niccolini M., Vannozzi I., et al. Comparison of steroid receptor expression in normal, dysplastic, and neoplastic canine and feline mammary tissues. Research in Veterinary Science 2005, 79:225-232.
23. Misdorp W. Tumours of the mammary gland. Tumors in Domestic Animals 2002, 575-606. Blackwell Publishing Company, Ames. D.J. Meuten (Ed.).
24. Modjtahedi H., Essapen S. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs 2009, 20:851-855.
25. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clinical Cancer Research 2004, 10:5367-5374.
26. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
27. Potemski P., Kusinska R., Watala C., Pluciennik E., Bednarek A.K., et al. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 2005, 69:478-485.
28. Preziosi R., Sarli G., Benazzi C., Marcato P.S. Detection of proliferating cell nuclear antigen (PCNA) in canine and feline mammary tumours. Journal of Comparative Pathology 1995, 113:301-313.
29. Rakha E.A., El-Sayed M.E., Reis-Filho J., Ellis I.O. Pathobiological aspects of basal-like breast cancer. Breast Cancer Research and Treatment 2009, 113:411-422.
30. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., Habashi H.O., Green A.R., et al. Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clinical Cancer Research 2009, 15:2302-2310.
31. Rakha E.A., Reis-Filho J.S., Ellis I.O. Basal-like breast cancer: a critical review. Journal of Clinical Oncology 2008, 26:2568-2581.
32. Rampaul R.S., Pinder S.E., Wencyk P.M., Nicholson R.I., Blamey R.W., et al. Epidermal growth factor receptor status in operable invasive breast cancer: is it of any prognostic value?. Clinical Cancer Research 2004, 10:2578.
33. Restucci B., Papparella S., Maiolino P., De Vico G. Expression of vascular endothelial growth factor in canine mammary tumors. Veterinary Pathology 2002, 39:488-493.
34. Rutteman G.R., Withrow S.J., MacEwen E.G. Tumors of the mammary gland. Small Animal Clinical Oncology 2001, 455-477. Saunders, Philadelphia. S.J. Withrow, B.R. MacEwen (Eds.).
35. Sassi F., Benazzi C., Castellani G., Sarli G. Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Veterinary Research 2010, 6:5.
36. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:10869-10874.
37. Sorlie T., Wang Y., Xiao C., Johnsen H., Naume B., et al. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. BMC Genomics 2006, 7:127.
38. Stefanou D., Batistatou A., Nonni A., Arkoumani E., Agnantis N.J. p63 expression in benign and malignant breast lesions. Histology and Histopathology 2004, 19:465-471.
39. Tang P., Skinner K.A., Hicks D.G. Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?. Diagnostic Molecular Pathology 2009, 18:125-132.
40. Van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
41. van de Rijn M., Perou C.M., Tibshirani R., Haas P., Kallioniemi O., et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. American Journal of Pathology 2002, 161:1991-1996.